Professional
Added to YB: 2024-01-24
Pitch date: 2024-01-24
NVO [bullish]
Novo Nordisk A/S
-55.9%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 701.43
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Hermes Investment holding: Novo Nordisk ($NVO)
$NVO Wegovy obesity drug w/ semaglutide in high demand; SELECT trial: 20% heart risk reduction in obese adults; treats 36.4M, extends 1.9M lives; 30% on Wegovy lost 20%+ weight; addresses diabetes & obesity health impacts like heart disease, cancer; strong pipeline despite $LLY competition
Read full article (2 min)